DOI: 10.1111/echo.13645
O R I G I N A L I N V E S T I G AT I O N
Relationship of cardiac troponin to systolic global longitudinal strain in hypertrophic cardiomyopathy Anushree Agarwal MD1,3 | Rayan Yousefzai MD1 | Kambiz Shetabi MD1 | Fatima Samad MD1 | Saurabh Aggarwal MD2 | Chi Cho MS1 | Michelle Bush NP1 | M. Fuad Jan MBBS, MD1 | Bijoy K. Khandheria MD1 | Timothy E. Paterick MD, JD1 | A. Jamil Tajik MD1 1 Aurora Cardiovascular Services, Aurora Sinai/ Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, USA 2
Creighton University School of Medicine, Omaha, NE, USA 3
University of California, San Francisco, Division of Cardiology, Adult Congenital Cardiology Program, San Francisco, CA, USA Correspondence A. Jamil Tajik, MD, Director, Cardiac Specialty Center, Aurora St. Luke’s Medical Center, Milwaukee, WI, USA. Email: [email protected]
Background: A high proportion of stable hypertrophic cardiomyopathy (HCM) patients have elevated serum cardiac troponin I (cTnI), but its clinical and echocardiographic determinants are unknown. Our objective was to determine the prevalence and clinical predictors of positive troponin (cTnI+) in a well-defined population of HCM patients using a highly sensitive assay. Methods: We retrospectively interrogated medical records of 167 stable HCM patients from 1/2011 to 3/2014. cTnI >0.04 ng/mL was considered positive. Results: Thirty-four percent were troponin-positive (median cTnI was 0.1 [0.07, 0.2] ng/dL). cTnI as a continuous variable correlated positively with maximal left ventricular wall thickness (LVT), maximal interventricular septal thickness, and global longitudinal strain (GLS) (P
O R I G I N A L I N V E S T I G AT I O N
Relationship of cardiac troponin to systolic global longitudinal strain in hypertrophic cardiomyopathy Anushree Agarwal MD1,3 | Rayan Yousefzai MD1 | Kambiz Shetabi MD1 | Fatima Samad MD1 | Saurabh Aggarwal MD2 | Chi Cho MS1 | Michelle Bush NP1 | M. Fuad Jan MBBS, MD1 | Bijoy K. Khandheria MD1 | Timothy E. Paterick MD, JD1 | A. Jamil Tajik MD1 1 Aurora Cardiovascular Services, Aurora Sinai/ Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, USA 2
Creighton University School of Medicine, Omaha, NE, USA 3
University of California, San Francisco, Division of Cardiology, Adult Congenital Cardiology Program, San Francisco, CA, USA Correspondence A. Jamil Tajik, MD, Director, Cardiac Specialty Center, Aurora St. Luke’s Medical Center, Milwaukee, WI, USA. Email: [email protected]
Background: A high proportion of stable hypertrophic cardiomyopathy (HCM) patients have elevated serum cardiac troponin I (cTnI), but its clinical and echocardiographic determinants are unknown. Our objective was to determine the prevalence and clinical predictors of positive troponin (cTnI+) in a well-defined population of HCM patients using a highly sensitive assay. Methods: We retrospectively interrogated medical records of 167 stable HCM patients from 1/2011 to 3/2014. cTnI >0.04 ng/mL was considered positive. Results: Thirty-four percent were troponin-positive (median cTnI was 0.1 [0.07, 0.2] ng/dL). cTnI as a continuous variable correlated positively with maximal left ventricular wall thickness (LVT), maximal interventricular septal thickness, and global longitudinal strain (GLS) (P
